[{"orgOrder":0,"company":"NIHR","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NIHR","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NIHR \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NIHR \/ Undisclosed"},{"orgOrder":0,"company":"U.S. Army Medical Research and Development Command","sponsor":"SIGA Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"U.S. Army Medical Research and Development Command","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"U.S. Army Medical Research and Development Command \/ SIGA Technologies","highestDevelopmentStatusID":"1","companyTruncated":"U.S. Army Medical Research and Development Command \/ SIGA Technologies"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ US Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ US Department of Defense"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"SIGA Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ SIGA Technologies","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ SIGA Technologies"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Meridian Medical Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Meridian Medical Technologies \/ SIGA Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Meridian Medical Technologies \/ SIGA Technologies"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Meridian Medical Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Meridian Medical Technologies","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Meridian Medical Technologies"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Public Health Agency of Canada","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Public Health Agency of Canada"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ US Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ US Department of Defense"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Undisclosed"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Meridian Medical Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Meridian Medical Technologies \/ Public Health Agency of Canada","highestDevelopmentStatusID":"15","companyTruncated":"Meridian Medical Technologies \/ Public Health Agency of Canada"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"ASEAN","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Divestment","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ ASEAN","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ ASEAN"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ BARDA"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Undisclosed"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Patheon","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Patheon","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Patheon"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ US Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ US Department of Defense"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Undisclosed"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Undisclosed"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ University of Oxford","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ University of Oxford"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Biomedical Advanced Research and Development Authority | PPD","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIGA Technologies \/ Biomedical Advanced Research and Development Authority | PPD","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Biomedical Advanced Research and Development Authority | PPD"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Biomedical Advanced Research and Development Authority | PPD","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIGA Technologies \/ Biomedical Advanced Research and Development Authority | PPD","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Biomedical Advanced Research and Development Authority | PPD"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIGA Technologies \/ US Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ US Department of Defense"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIGA Technologies \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"||Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoViricides \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Undisclosed"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Immunology","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0.40999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.40999999999999998,"dosageForm":"Undisclosed","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ BARDA"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"JPEO-CBRND","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Immunology","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"SIGA Technologies \/ JPEO-CBRND","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ JPEO-CBRND"},{"orgOrder":0,"company":"Marina Klein","sponsor":"McGill University Health Centre Research Institute | University Health Network, Toronto | Unity Health Toronto | University of British Columbia | CIHR Canadian HIV Trials Network","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Marina Klein","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marina Klein \/ McGill University Health Centre Research Institute | University Health Network, Toronto | Unity Health Toronto | University of British Columbia | CIHR Canadian HIV Trials Network","highestDevelopmentStatusID":"10","companyTruncated":"Marina Klein \/ McGill University Health Centre Research Institute | University Health Network, Toronto | Unity Health Toronto | University of British Columbia | CIHR Canadian HIV Trials Network"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"KaliVir Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Tecovirimat","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIGA Technologies \/ KaliVir Immunotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SIGA Technologies \/ KaliVir Immunotherapeutics"}]
Find Clinical Drug Pipeline Developments & Deals for Tecovirimat
Details :
Tepoxx (tecovirimat) is an oral orthopoxvirus VP37 envelope-wrapping protein inhibitor, Currently, it is being evaluated in the mid-stage clinical trial for the treatment of Orthopoxviruses.
Details :
Tpoxx (tecovirimat) is an antiviral drug candidate that targets orthopoxvirus VP37 envelope wrapping protein. It is being evaluated for the treatment of mpox.
Details :
The agreement aims for the procurement of Tpoxx (tecovirimat), an antiviral, approved in the US and Canada for the treatment of smallpox and authorized in EU and the UK for smallpox, mpox and cowpox.
Details :
Tpoxx (tecovirimat) is an oral orthopoxvirus VP37 envelope-wrapping protein inhibitor, Currently, it is being evaluated in the mid-stage clinical trial for the treatment of Monkeypox Virus.
Details :
The agreement aims to expand access to Tpoxx (tecovirimat), a novel small-molecule drug for the treatment of smallpox, to the member states in the ASEAN.
Details :
SIGA will lead international promotions for oral TPOXX, an FDA-approved drug for smallpox, while maintaining its contractual relationship with Meridian to ensure continuity for key customers.
Details :
TPOXX (tecovirimat), also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
Details :
Tecovirimat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Mpox, Monkeypox.
Sponsor :
McGill University Health Centre Research Institute | University Health Network, Toronto | Unity Health Toronto | University of British Columbia | CIHR Canadian HIV Trials Network
Details :
Tecovirimat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Mpox, Monkeypox.
Sponsor :
McGill University Health Centre Research Institute | University Health Network, Toronto | Unity Health Toronto | University of British Columbia | CIHR Canadian HIV Trials Network
Details :
Tecovirimat (also known as TPOXX®) prevents the virus from leaving infected cells, stopping its spread within the body for monkeypox based on promising results from initial studies in animals and evidence of safety in healthy human volunteers.
Reset All
